A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Vicriviroc (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2018 Status changed from not yet recruiting to recruiting.
- 22 Aug 2018 New trial record